Dübendorf ZH/St.Gallen - The scientist Peter Nirmalraj is seeking to develop a simple blood test to help diagnose dementia. A pilot study carried out in conjunction with the Clinic for Neurology at the Cantonal Hospital of St.Gallen has now been brought to a successful close.

Empa researcher Peter Nirmalraj analyzes blood samples using atomic force microscopy (AFM). Image: Empa
Empa researcher Peter Nirmalraj analyzes blood samples using atomic force microscopy (AFM). Image: Empa

Peter Nirmalraj, a researcher at the Swiss Federal Laboratories for Materials Science and Technology (Empa), is on the lookout for signs of dementia in the blood. As part of a successfully completed pilot study, Nirmalraj has, according to a press release issued by Empa, detected a pattern in the patients used as test subjects: those suffering from Alzheimer's disease had large amounts of protein fibers made up of beta-amyloid peptides and tau proteins. These proteins were able to assemble into fibers several hundred nanometers long. In contrast, Nirmalraj, who works out of Dübendorf in the canton of Zurich as well as St.Gallen, counted only a handful of fibers on red blood cells in healthy test subjects.

It was already known that both proteins are more frequently found in the bodily fluids of dementia patients. However, their exact role in neurodegenerative diseases has not yet been fully deciphered. The technologies developed by Nirmalraj are not only able to determine the total volume of these proteins, but also provide crucial visible insights into the differences with regard to the shape and condition of the protein accumulations. For his blood observations in the nanometer range, Nirmalraj uses atomic force microscopy (AFM), and has produced a video to outline and explain his approach.

Watch the video

Together with neurologists from the Cantonal Hospital of St.Gallen, Nirmalraj analyzed blood samples of 50 patients in addition to 16 healthy people. He had no prior knowledge as to the state of health of the people to whom the samples belonged. “This was the only way to make sure the interpretation of the data remained objective”, Nirmalraj explains. His findings have now been published in the specialist journal “Science Advances”.

If a valid blood test can be successfully developed on the basis of this method, then “people with suspected Alzheimer's would be spared the unpleasant puncture of the spinal canal in order to be able to diagnose the disease reliably”, Nirmalraj states. However, there is still some way to go before this prospect is a reality: the next step will involve Nirmalraj and his team expanding and corroborating the clinical data basis.

Sign up for biotech news from Greater Zurich

The subscription service is currently unavailable. Please check again later.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line. 

+41 44 254 59 59


info@greaterzuricharea.com